Session 7 – Cell & Gene Therapies Date: 26 July (Friday) 9:00 – 12:00 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Global Head of R &D, Cell & Gene Therapy
Madhusudan V. Peshwa, Ph.D., currently serves as Global Head of R&D for Cell and Gene Therapies (CGT). Dr. Peshwa’s responsibilities encompass GEHC’s CGT product and service portfolio to enable and accelerate the development of robust, scalable, industrialized manufacturing and delivery of cell and gene therapies. These include Instrumentation, Single-use Disposables, Culture Medium, Reagents & Consumables, Product & Process Characterization, and Digital & Informatics facilitating process automation, integration with higher level business processes and predictive analytics.
Prior to joining GE Healthcare Life Sciences, Dr. Peshwa held various Executive positions at MaxCyte, Inc., NewNeural LLC, and Dendreon Corporation; leading the development and commercialization of platform technologies and immune cell therapies; including personalized Cancer Vaccines, CAR-engineered T-cell immunotherapies and gene-edited Stem Cell therapies. In addition to his vast industry experience, he has been the principal/co-investigator on multiple research studies, has been issued six US patents for cell therapies, and has served in various advisory capacities to industry, government, regulatory and financial organizations. Dr. Peshwa earned his undergraduate degree in Chemical Engineering from the Indian Institute of Technology (Kanpur, India) and his PhD in Chemical Engineering from the University of Minnesota (Minneaplois, MN) Session Speech Title & Synopsis: Industrializing Cell & Gene Therapies: Designing and Managing a Complex Therapeutic Supply Chain
This presentation will compare and contrast key elements of biologics and cell & gene therapy manufacturing and delivery from the perspective of anticipated future market demand. The challenges of commercializing living therapies include scale up and scale out manufacturing, cold-chain logistics, data management, facilities design and utilization, as well as a host of other critical supply chain elements. We’ll look at how process developers introduce advanced manufacturing capabilities to realize the commercial and clinical potential of this novel class of medicines.